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Abstract: Smenospongine, a sesquiterpene aminoquinone isolated from the marine sponge 
Dactylospongia elegans, was previously reported by us to induce erythroid differentiation 
and G1 phase arrest of K562 chronic myelogenous leukemia cells. In this study, we 
investigated the effect of smenospongine on the cell cycles of other leukemia cells, 
including HL60 human acute promyelocytic leukemia cells and U937 human histiocytic 
lymphoma cells by flow cytometric analysis. Smenospongine induced apoptosis dose-
dependently in HL60 and U937 cells. The smenospongine treatment increased expression 
of p21 and inhibited phosphorylation of Rb in K562 cells, suggesting the p21-Rb pathway 
play an important role in G1 arrest in K562 cells. However, the p21 promoter was not 
activated by the smenospongine treatment based on a luciferase assay using the transfected 
K562 cells. Smenospongine might induce p21 expression via another mechanism than 
transactivation of p21 promoter.  
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1.  Introduction 
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell cancer caused by the Bcr-Abl 
tyrosine kinase which arised from Philadelphia chromosome (Ph) translocation [1,2]. The only known 
curative therapy for CML is allogeneic bone marrow transplant (BMT). However, the treatment-
related toxicity is severe, with reported mortality at about 30% [3]. A selective inhibitor of Bcr-Abl, 
imatinib mesylate (Glivec
®), was developed as the first molecule-targeted anticancer drug [4]. Within 
the last decade, imatinib has proven to be highly efficacious for treatment of CML. However, with the 
widespread use of this drug, the resistance in some patients has been well reported, which is usually 
caused by mutations within Bcr-Abl [3,5,6]. Therefore, development of alternative drugs to imatinib 
for CML treatment has been expected. In addition, since Bcr-Abl is only present in CML and about 
20% of cases with acute lymphoblastic leukemia, imatinib shows its limitations on other leukemia 
diseases. On the contrary, it was reported that FK228, a histone deacetylase (HDAC) inhibitor, was 
indicated to be therapeutically effective in treating not only CML, but also AML (acute myelogenous 
leukemia) and lymphocytic leukemia [7-9]. Consequently, there is great interest in discovering and 
developing similar  antiumor agents showing therapeutic effects on all leukemias. 
As a part of our discovery of new anticancer drug candidate from natural resources, we have been 
searching for new differentiation-inducing substances or cell cycle inhibitors for CML cells [10,11]. 
With the guidance of a bioassay method for erythroid differentiation of K562 CML cells, we isolated 
smenospongine, a sesquiterpene aminoquinone, from the Indonesian marine sponge Dactylospongia 
elegans. Smenospongine induced cell cycle arrest at the G1 phase and increased p21 expression 
[12,13]. One question, whether smenospongine shows the same effect on other leukemia cells or not, 
remained unclear. We recently investigated the effect of smenospongine on other leukemia cells such 
as HL60 and U937 by cell cycle analysis and further investigated the mechanism for the G1 arrest in 
K562 cells.  
2. Results and Discussion 
2.1. Effect of smenospongine on cell cycle distribution in K562, HL60, and U937 cells 
Our previous study showed that smenospongine (Figure 1) induced G1 arrest in K562 cells [12]. 
To investigate whether this compound has the same effect on other leukemia cells or not, cell cycle 
analysis for HL60 and U937 cells together with K562 cells was carried out. Various concentrations of 
smenospongine as DMSO solution were added to the randomly cultured K562, HL60, and U937 cells, 
respectively. After 24 h, the cells were collected for cell cycle analysis. As a result, smenospongine 
induced G1 phase arrest in K562 cells at 15 μM concentration (Figure 2A), which is consistent with 
our previous report [12]. G1 arrest was not found in HL60 and U937 cells, but sub-G1 accumulation, 
which indicates apoptosis, was observed. And the induction of apoptosis was shown to be dose-
dependently (Figure 2B, 2C). In order to check whether this is attributed to the difference of the 
sensitivity for individual cells or not, we further analyzed with lower doses of smenospongine which 
did not induce apoptosis in both cells. However, no G1 accumulation was detected yet in both cells 
(data not shown). This suggests that smenospongine might affect different leukemia cells via the 
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2.2. Effect of smenospongine on expression of p21 and phosphorylation of Rb 
To demonstrate that the G1 phase arrest by smenospongine is attributed to p21 induction and 
inhibition of the phosphorylation of Rb, which located in the downstream of p21 and is known to play 
a key role in cell cycle progression from G1 to S phase, p21 expression and phosphorylation of Rb in 
K562 cells were examined. A 15 μM concentration of smenospongine was added to K562 cells. The 
cells treated for different length of time were collected, and the respective cell lysate was prepared for 
Western blotting analysis. The expression of p21 was detected after 12 h and increased in a time-
dependent manner until 48 h (Figure 3). Accordingly, the underphosphorylated Rb protein (URb) was 
also detected after 24 h and highly increased until 48 h, indicating that the phosphorylation of Rb 
protein was inhibited by the smenospongine treatment for 24 to 48 h. This result suggests that the p21-
Rb pathway might play an important role in the G1 phase arrest in K562 cells induced by 
smenospongine. 
2.3. Effect of smenospongine on activation of p21 promoter  
Since K562 cell is known as p53-negative cell [14], the p21 induction can be considered as p53-
independent. Furthermore, the induction of p21 mRNA expression by smenospongine was also 
observed by RT-PCR analysis (data not shown). This suggested the possibility that the p21 expression 
was induced by trans-activating p21 promoter. In order to investigate whether smenospongine can 
trans-activate p21 promoter or not, we transfected K562 cells with pWWP, a human wild-type p21 
promoter-luciferase fusion plasmid. Luciferase assay was carried out with the transfected cells after 
DMSO, smenospongine or trichostatin A (TSA) treatment. TSA was used as a positive control, since it 
was previously reported to activate p21 promoter [15,16]. As a result, the luciferase activity of the 
smenospongine-treated K562 cells was not significantly increased, while the TSA-treated cells showed 
about 200 fold enhancement over those DMSO-treated, indicating that smenospongine can not activate 
p21 promoter (Figure 4). Therefore, we postulate that smenospongine might act by stabilizing p21 
mRNA to increase mRNA and protein expression and lead to G1 arrest in K562 cells via p21-Rb 
pathway. The mechanism of smenospongine to induce apoptosis in HL60 and U937 cells, including 
effect on p21 expression, is under investigation. 
 
O
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Figure 1. Chemical structure of smenospongineMar. Drugs 2008, 6                                                  
 
 
483
Figure 2. Effect of smenospongine on cell cycle distribution of K562, HL60, and U937 
cells. A suspension of K562 (A), HL60 (B), and U937 (C) cells (2×10
5 cells/2ml/well) was 
incubated in the presence or absence of various concentrations of smenospongine in an 8-
well plate under a 5% CO2 atmosphere at 37°C, respectively. After 24 h, the cells were 
collected and dyed with DNA-Prep Reagents Kit for cell cycle analysis. The analysis was 
carried out with flow cytometer (λex = 493 nm, λem = 630 nm) and quantified by ModFit 
Software. 
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Figure 3. Effect of smenospongine on expression of p21 and phosphorylation of Rb. K562 
cells (1×10
6 cells/10ml) were incubated with 15 μM smenospongine for the indicated time 
periods.  The cell lysate was prepared and applied to 4-20% SDS-PAGE. After being 
transferred to PVDF membrane, the blots were exposed to anti-Cip1/WAF-1/p21, anti-
human underphosphorylated Rb (URb) or anti-β-actin antibody and then anti-mouse IgG 
HRP-conjugated antibody.  The bound antibodies were visualized using an Enhanced 
Chemiluminescence (ECL) system.  
 
 
Figure 4. Activation of p21 promoter by smenospongine and TSA in the transfected K562 
cells. K562 cells were transfected with pWWP, which is a human wild-type p21 promoter-
luciferase fusion plasmid, by DEAE-Dextran Transfection Kit. The cells were incubated at 
a density of 5×10
4 cells/ml in a 12-well plate for 24 h. 125 ng of pWWP in DEAE-Dextran 
was added to perform transfection for 15 min. The transfected cells were further incubated 
for 24 h and then treated by DMSO, smenospongine or TSA for another 24 h. Finally, the 
cells were collected and the luminescence was measured by using MICRO LUMAT Plus 
LB96V. The activation of p21 promoter was evaluated by the relative light intensity 
compared with that of the control (cells treated with DMSO only). 
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3. Conclusions 
Smenospongine, a sesquiterpene aminoquinone isolated from the marine sponge of Dactylospongia 
elegans, induced G1 arrest in K562 cells, while induced apoptosis in HL60 and U937 cells. P21-Rb 
pathway is considered to play an important role in its effect of the G1 arrest in K562 cells. 
4. Experimental Section 
4.1. Materials 
4-20% gel cassette was purchased from Daiichi Pure Chemicals Co., Ltd.  DNA-Prep Reagents Kit 
was from Coulter Co.  RPMI 1640 and DMEM Medium were from Nissui Pharmaceutical Co., Ltd.  
Polyvinylidene fluoride (PVDF) membrane was from Amersham Pharmacia Biotec. UK Ltd.  Other 
reagents were from Sigma Co., Ltd. or Wako Pure Chemical Industries Co., Ltd unless stated 
specifically. 
4.2. Cell culture 
K562, HL60, and U937 cells, which were provided by RIKEN Cell Bank, were routinely 
maintained in the RPMI 1640 (for K562 and U937) or DMEM (for HL60) medium supplemented with 
10% fetal bovine serum, kanamycin (100 μg/mL) and glutamine (0.44 mg/mL) at 37°C in a humidified 
atmosphere containing 5% CO2. 
4.3. Antibodies 
Anti-Cip1/WAF-1/p21 antibody was purchased from Upstate Biotechnology Inc.; anti-human 
underphosphorylated Rb antibody was from BD Biosciences; anti-β-actin antibody was from Sigma 
Co., Ltd; anti-mouse horseradish peroxidase (HRP) conjugated antibody was from Nacalai Tesque Inc. 
4.4. Isolation and identification of smenospongine 
Smenospongine was isolated from the marine sponge Dactylospongia elegans (collected in 
Indonesia in 2001) as described previously [12]. Briefly, the dried marine sponge was cut into pieces 
and extracted with methanol. The resulting methanol extract was subjected to solvent partition to give 
hexane, 90% methanol, n-BuOH, and H2O soluble portions.  The 90% methanol soluble portion was 
separated by repeated SiO2 column, reversed-phase column, and high-performance liquid 
chromatography (HPLC) to obtain smenospongine.  The structure of smenospongine was identified by 
comparison of the mass and NMR data with those reported [17].  
4.5. Flow cytometric analysis of cell cycle 
The cell suspension (2×10
5 cells/2 ml/well) of K562, HL60 or U937 cells was placed in an 8-well 
plate and incubated for 24 h at 37°C under a 5% CO2 atmosphere.  The DMSO solution of the testing 
sample (10 μl) was added and further incubated for 24 h.  The cells were harvested and collected, 
followed by staining with DNA-Prep Reagents Kit for 20 min.  Then, the supernatant was removed by Mar. Drugs 2008, 6                                                  
 
 
486
centrifugation, and the cell pellets were re-suspended in 500 μl of D-PBS (-). After being filtered with 
a 40−μm nylon mesh filter, the cell suspension was available for cell cycle analysis by flow cytometer 
(λex = 493 nm, λem = 630 nm). The analysis result was quantified by ModFit software (Verity 
Software, Topsham, ME).  
4.6. Western blotting analysis 
The cell suspension (1×10
6 cells/10 mL) of K562 cells was incubated in a flask together with 15 μM 
of smenospongine for the indicated length of time under a 5% CO2 atmosphere at 37°C.  The cells 
collected by centrifugation (1000 g for 3 min at 4°C) were washed with cold PBS and treated with 
lysis buffer (50 mM Tris-HCl, pH7.2; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM 
EDTA; 1 mM PMSF; 1% proteinase inhibitor cocktail) to furnish a cell lysate.  Protein assay was 
carried out using a Bio-Rad protein assay kit.  After boiling at 95°C for 5 min in the sample buffer 
(0.125 M Tris-HCl (pH 6.8), 10% 2-mercaptoethanol, 4% SDS, 10% sucrose, 5% bromophenol blue), 
the equal amounts of protein were subjected to SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
and then transferred to PVDF membrane.  The membrane was blocked with 5% milk TBS (Tween 
PBS) and exposed to anti-Cip1/WAF-1/p21, anti-human underphosphorylated Rb, or anti-β-actin 
antibody and then anti-mouse IgG HRP-conjugated antibody.  The bound antibodies were visualized 
using an Enhanced Chemiluminescence (ECL) system.  
4.7. Transfection of K562 cells and luciferase assay 
K562 cells were transfected with a human wild-type p21 promoter-luciferase fusion plasmid, 
pWWP, by DEAE-Dextran (CellPhect Transfection Kit, Amersham Pharmacia Biotech). The cells 
were incubated at a density of 5×10
4 cells/mL in a 12-well plate for 24 h. The 125 ng of the reporter 
plasmid DNA, pWWP, in DEAE-Dextran was added to perform transfection for 15 min. The 
transfected cells were further incubated for 24 h followed by DMSO, smenospongine or TSA 
treatment for another 24 h. Finally, the cells were collected for luciferase assay, which was carried out 
by use of the luciferase assay system (E1501, Promega) as described previously  [18]. The 
luminescence was measured by using MICRO LUMAT Plus LB96V (BERTHOLD) and WING LOW 
software. The activation of p21 promoter was evaluated by the relative light intensity compared with 
that of the control (cells treated with DMSO only) [18].  
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